Search

everythinglearnresearchcommunity

for

Search:↓

Finasteride for hair loss may increase the risk of certain cancers and has side effects; better regulation and education on its use are needed.

Oncoplastic breast surgery is more cost-effective than standard lumpectomy for large-breasted women despite being more expensive.

The term "porokeratotic adnexal ostial nevus" is proposed to unify overlapping skin conditions involving eccrine and hair follicles.

Local hormonal treatment for vulvovaginal atrophy is likely safe for women with estrogen receptor-positive breast cancer on aromatase inhibitors.

The document concludes that modern photo stories help represent and challenge how breast cancer affects women's identities and societal norms.

The new patient-controlled expansion technique for breast reconstruction is safe, efficient, and cost-effective.

Chemotherapy worsens nutritional status in breast cancer patients, requiring targeted nutritional strategies.

Managing side effects of endocrine therapy is crucial to improve adherence and survival in breast cancer patients.

Docetaxel treatment for breast cancer can cause permanent hair loss.

Some early breast cancer patients have long-term hair loss after chemotherapy, especially older and postmenopausal women.

Docetaxel and paclitaxel for breast cancer can cause permanent, severe hair loss.

Compound N4 effectively kills breast cancer cells and compounds N2 and N3 have strong antibacterial and antifungal properties.

Flow cytometry was effective in diagnosing metastatic breast cancer in a bone marrow sample.

The hair keratin gene KRT81 is found in both normal and breast cancer cells and helps them invade surrounding tissues.

ADCs can effectively treat breast cancer but may cause side effects like nausea and hair loss.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

Spironolactone use is not linked to an increased risk of breast cancer, but caution is advised for high-risk patients.

Low-dose oral minoxidil improved hair growth when topical treatments failed.

Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.

Low-dose oral minoxidil combined with topical minoxidil improves hair growth in breast cancer patients with therapy-induced hair loss.

The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.

A 50-year-old woman with breast cancer developed an autoimmune skin disorder, highlighting the need for thorough checks and team-based treatment.

Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.

Multimodal primary treatment improves survival in premenopausal breast cancer patients and is also beneficial for postmenopausal women.

Low Vitamin D receptor levels in breast cancer are linked to worse outcomes and more bone metastases, and could be a marker for prognosis.

RANK is a key target in breast cancer treatment due to its role in tumor growth and bone metastasis.

The rib-sparing technique in breast reconstruction may lead to more complications without reducing the need for further surgery.

A young woman with severe symptoms of CPAN improved with intensive treatment but needed a leg amputation.

Hair loss from hormone therapy in breast cancer patients can be improved with minoxidil treatment.

Taking 5-alpha reductase inhibitors does not increase breast cancer risk in men.